On August 28, 2018 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported that the Company will present on three panels at the B. Riley FBR Annual Healthcare Conference to be held on September 4, 2018 in New York City, as well as meeting with investors (Press release, Cellular Biomedicine Group, AUG 28, 2018, View Source [SID1234529160]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The panels will range in topics from the latest development in CAR-T Cell Therapies to the role Chinese capital can play to fund innovation.